Establish MeMed BV™ Performance for Differentiating Bacterial From Viral Infection in Suspected Acute Infection Patients (APOLLO STUDY)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1384 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-03

Study Completion Date

2020-11-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, multi-center, observational, blinded study, enrolling pediatric and adult subjects. Eligible ED\\Urgent care and hospital admitted patients with symptoms consistent with acute bacterial or viral infection and healthy subjects will be recruited according to the eligibility criteria. Each participant will undergo a thorough investigation upon recruitment that includes documenting clinical, radiological, laboratory and microbiological information for determining their health status.

Follow-up data will be collected via a phone call. Diagnostic performance of the MeMed BV™ Test for differentiating bacterial from viral infection will be assessed using an expert adjudication comparator method.

The study will be run in a blinded fashion: site personnel will be blinded to the comparator method outcomes, and the expert panel will be blinded to the results of the index test. Results of the index test will not be revealed to the attending clinician and so will not influence patient management.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO

NCT05897801

Viral Infection Bacterial Infections Multi-antibiotic Resistance +1 more

COMPLETED

Access MeMed BV Assay Clinical Study Collection Protocol - Infectious Adult and Pediatric Cohorts

NCT06379061

Infection, Bacterial Infection Viral

COMPLETED

Video Instruction in the Collection of Clean Catch Urine in Pregnant Women Undergoing Testing for Urine Culture

NCT03658356

Asymptomatic Bacteriuria in Pregnancy

UNKNOWN NA

Control of Trichomoniasis

NCT00334555

Trichomoniasis

COMPLETED NA

A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test

NCT00682851

Bacterial Vaginosis Urogenital Infection by Trichomonas Vaginalis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Infectious

Eligible pediatric and adult patients from ED\\Urgent care and hospital admitted, with symptoms consistent with acute bacterial or viral infection.

MeMed BV

Intervention Type DIAGNOSTIC_TEST

The MeMed BV™ Test is an immunoassay that measures three non-microbial (host) proteins (TRAIL, IP-10, and CRP) in adult and pediatric serum samples. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. The test is indicated for use in patients presenting to the ED, urgent care center and inpatients with suspected acute bacterial or viral infection. The MeMed BV™ Test generates a numeric score that falls within discrete interpretation bins based on the increasing likelihood of bacterial infection. The MeMed BV™ test is intended for in vitro diagnostic use only.

Healthy

For the purpose of establishing a normal reference range.

MeMed BV

Intervention Type DIAGNOSTIC_TEST

The MeMed BV™ Test is an immunoassay that measures three non-microbial (host) proteins (TRAIL, IP-10, and CRP) in adult and pediatric serum samples. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. The test is indicated for use in patients presenting to the ED, urgent care center and inpatients with suspected acute bacterial or viral infection. The MeMed BV™ Test generates a numeric score that falls within discrete interpretation bins based on the increasing likelihood of bacterial infection. The MeMed BV™ test is intended for in vitro diagnostic use only.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MeMed BV

The MeMed BV™ Test is an immunoassay that measures three non-microbial (host) proteins (TRAIL, IP-10, and CRP) in adult and pediatric serum samples. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. The test is indicated for use in patients presenting to the ED, urgent care center and inpatients with suspected acute bacterial or viral infection. The MeMed BV™ Test generates a numeric score that falls within discrete interpretation bins based on the increasing likelihood of bacterial infection. The MeMed BV™ test is intended for in vitro diagnostic use only.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent must be obtained from the patient or his/her legal guardian. For children under 18 years old, written informed consent from the legal guardian and assent from the patient (depending on the local requirements)
* Over 90 days of age
* Clinical suspicion of acute bacterial or viral infection
* Temperature ≥ 37.8°C (100°F) (any body site, any measurement device, including self-reported) or tactile fever, either of them noted at least once within the last 7 days
* Current disease duration ≤ 7 days

Exclusion Criteria

* Another unrelated episode of febrile infection within the past 2 weeks
* Suspicion and/or confirmed diagnosis of infectious gastroenteritis/ colitis
* \>48 hours of oral antibiotic treatment
* \>12 hours of intravenous\\intramuscular antibiotic treatment
* HIV, HBV, or HCV infection (self-declared or known from medical records)
* A proven or suspected infection on presentation with Mycobacterial (e.g. Tuberculosis, MAC), parasitic or fungal (e.g. Candida, Histoplasma, Aspergillus) pathogen
* Active inflammatory disease (e.g. IBD, SLE, JIA, RA, Kawasaki, other vasculitis)
* Major trauma and\\or burns in the last 7 days
* Major surgery in the last 7 days
* Congenital immune deficiency (CID)
* Acquired immune deficiency\\modulation state including:

* Active malignancy
* Current treatment with immune-suppressive or immune-modulating therapies, including without limitations:

* Administration of P.O.\\IV\\IM high dose steroids \>1mg/kg/day prednisone (or equivalent) at some point in the past 10 days or daily continuous use of steroids \> 0.25 mg/kg/day in the past 7 days
* Monoclonal antibodies, anti-TNF agents
* Intravenous immunoglobulin (IVIG)
* Cyclosporine, Cyclophosphamide, Tacrolimus, Azathioprine, Methotrexate
* G/GM-CSF, Interferons
* Post solid organ/bone marrow transplant patients
* Asplenia, sickle cell disease
* Indwelling central venous catheter
* Cystic Fibrosis
* Pregnancy- self reported or medically known
* Other severe illnesses that affect life expectancy and quality of life such as:

* Severe psychomotor retardation
* Congenital metabolic disorder
* End stage renal disease, advanced heart failure (NYHA 3/4), advanced COPD (GOLD 3/4)

Minimum Eligible Age

90 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes